EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Discontinuation of Renin-Angiotensin System Inhibitors and Clinical Outcomes in Chronic Kidney Disease: A Systemic Review and Meta-Analysis

Chen Tang, Xin-Yan Wen, Ji-Cheng Lv, Su-Fang Shi, Xu-Jie Zhou, Li-Jun Liu, Hong Zhang

American Journal of Nephrology · 2023 · 54 (5-6) · 234-244

DOI: 10.1159/000531000 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift American Journal of Nephrology, online erschienen am 18.05.2023. Verfasst von Chen Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China, yu-gi-oh.tc@hotmail.com. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Kidney Failure, Chronic, Cardiovascular Diseases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Discontinuation of renin-angiotensin system (RAS) inhibitors is common in patients with chronic kidney disease (CKD), and the potential danger has been reported in several studies. However, a comprehensive analysis has not been conducted.

Objectives

This study sought to evaluate the effects of discontinuation of RAS inhibitors in CKD.

Method

Relevant studies up to November 30, 2022, were identified in the PubMed, Embase, Web of Science, and Cochrane Library databases. Efficacy outcomes included the composite of all-cause mortality, cardiovascular events, and end-stage kidney disease (ESKD). Results were combined using a random-effects or fixed-effects model, and sensitivity analysis used the leave-one-out method.

Results

Six observational studies and one randomized clinical trial including 244,979 patients met the inclusion criteria. Pooled data demonstrated that discontinuation of RAS inhibitors was associated with an increased risk of all-cause mortality (HR 1.42, 95% CI 1.23–1.63), cardiovascular event risk (HR 1.25, 95% CI 1.17–1.22), and ESKD (HR 1.23, 95% CI 1.02–1.49). In sensitivity analyses, the risk for ESKD was reduced. Subgroup analysis showed that the risk of mortality was more pronounced in patients with eGFR above 30 mL/min/m2 and in patients with hyperkalemia-related discontinuation. In contrast, patients with eGFR below 30 mL/min/m2 were at great risk of cardiovascular events.

Conclusions

The discontinuation of RAS inhibitors in patients with CKD was associated with a significantly increased risk of all-cause mortality and cardiovascular events. These data suggest that RAS inhibitors should be continued in CKD if the clinical situation allows.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicKidney Failure, ChronicCardiovascular DiseasesHumansRenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsEnzyme InhibitorsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Cardiovascular eventChronic kidney diseaseEnd-stage kidney diseaseMeta-analysisMortalityRenin-angiotensin system inhibitors

Substanzen

Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsEnzyme Inhibitors

Autor:innen und Institutionen

  • Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China, yu-gi-oh.tc@hotmail.com.
  • Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China, yu-gi-oh.tc@hotmail.com.
  • Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China, yu-gi-oh.tc@hotmail.com.
  • Department of Cardiology, Peking University First Hospital, Beijing, China.
  • Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
  • Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.

Zitieren

APA

Tang, C., Wen, X. Y., Lv, J. C., Shi, S. F., Zhou, X. J., Liu, L. J., & Zhang, H. (2023). Discontinuation of Renin-Angiotensin System Inhibitors and Clinical Outcomes in Chronic Kidney Disease: A Systemic Review and Meta-Analysis. American Journal of Nephrology, 54(5-6), 234-244. https://doi.org/10.1159/000531000

Vancouver

Tang C, Wen XY, Lv JC, Shi SF, Zhou XJ, Liu LJ, et al. Discontinuation of Renin-Angiotensin System Inhibitors and Clinical Outcomes in Chronic Kidney Disease: A Systemic Review and Meta-Analysis. American Journal of Nephrology. 2023;54(5-6):234-244. doi:10.1159/000531000

BibTeX
@article{Tang2023,
  author = {Tang, Chen and Wen, Xin-Yan and Lv, Ji-Cheng and Shi, Su-Fang and Zhou, Xu-Jie and Liu, Li-Jun and Zhang, Hong},
  title = {Discontinuation of Renin-Angiotensin System Inhibitors and Clinical Outcomes in Chronic Kidney Disease: A Systemic Review and Meta-Analysis},
  journal = {American Journal of Nephrology},
  year = {2023},
  volume = {54},
  number = {5-6},
  pages = {234--244},
  doi = {10.1159/000531000}
}
Kostenlos starten →